文献速递生殖医学

个体化促卵泡激素δ剂量降低日本IVF/ICSI患者OHSS风险:随机对照试验

Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
PubMed 文献 · Reprod Biomed Online · 2021-02-09

本研究为随机、对照、评估者盲、多中心、非劣效性试验,纳入347例日本IVF/ICSI患者,比较基于血清AMH和体重的个体化促卵泡激素δ固定剂量方案与常规促卵泡激素β方案。主要终点获卵数非劣效性成立(9.3 vs 10.5,95%CI下限-2.3),个体化组OHSS任何级别发生率11.2% vs 19.8%(P=0.021),中重度OHSS 7.1% vs 14.1%(P=0.027),每启动周期活产率23.5% vs 18.6%。

要点

  • 个体化促卵泡激素δ方案获卵数非劣效于常规促卵泡激素β方案。
  • 个体化方案使OHSS任何级别风险降低约一半(11.2% vs 19.8%)。
  • 中重度OHSS发生率个体化组显著更低(7.1% vs 14.1%)。

核心结论

  • 日本女性采用基于AMH和体重的个体化促卵泡激素δ剂量,获卵数非劣效于常规促卵泡激素β剂量。
  • 个体化方案显著降低OHSS发生率,且不损害活产率,获益-风险 profile 有利。

研究设计与样本

  • 随机、对照、评估者盲、多中心、非劣效性试验,纳入347例日本IVF/ICSI患者。
  • 个体化促卵泡激素δ剂量:AMH<15 pmol/l为12 µg/天;AMH≥15 pmol/l为0.10-0.19 µg/kg/天;最小6 µg/天,最大12 µg/天。
  • 对照常规促卵泡激素β:前5天150 IU/天,后续可调整剂量。
  • 主要终点为获卵数,预设非劣效界值-3.0个卵母细胞。

主要发现

  • 获卵数个体化组9.3个 vs 常规组10.5个,95%CI下限-2.3,非劣效性成立。
  • OHSS任何级别发生率个体化组11.2% vs 常规组19.8%(P=0.021)。
  • 中重度OHSS发生率个体化组7.1% vs 常规组14.1%(P=0.027)。
  • 每启动周期活产率个体化组23.5% vs 常规组18.6%。

关键数值与推荐

  • 个体化促卵泡激素δ剂量根据AMH分层:AMH<15 pmol/l固定12 µg/天;AMH≥15 pmol/l按体重0.10-0.19 µg/kg/天,范围6-12 µg/天。
  • 非劣效界值为获卵数差异-3.0个。
  • OHSS任何级别发生率11.2% vs 19.8%(P=0.021);中重度7.1% vs 14.1%(P=0.027)。

临床怎么用

  • 对日本IVF/ICSI患者,可考虑基于AMH和体重的个体化促卵泡激素δ固定剂量方案以降低OHSS风险。
  • 个体化方案获卵数略少但非劣效,且活产率未受损,可用于OHSS高风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: This study aimed to establish the efficacy and safety of ovarian stimulation with a follitropin delta individualized fixed-dose regimen based on serum anti-Müllerian hormone (AMH) concentration and body weight versus conventional follitropin beta dosing in Japanese women. DESIGN: This randomized, controlled, assessor-blind, multicentre, non-inferiority trial was conducted in 347 Japanese IVF/intracytoplasmic sperm injection patients. They were randomized to individualized follitropin delta (AMH <15 pmol/l: 12 µg/day; AMH ≥15 pmol/l: 0.10-0.19 µg/kg/day; minimum 6 µg/day; maximum 12 µg/day) or conventional follitropin beta (150 IU/day for the first 5 days, with potential subsequent dose adjustments). The primary end-point was the number of oocytes retrieved with a pre-specified non-inferiority margin (-3.0 oocytes). RESULTS: The primary trial objective was met, as non-inferiority was established for number of oocytes retrieved for individualized follitropin delta dosing compared with conventional follitropin beta dosing (9.3 versus 10.5; lower boundary of 95% confidence interval -2.3). The occurrence of ovarian hyperstimulation syndrome (OHSS) was reduced to approximately half with individualized compared with conventional dosing, with an incidence of 11.2% versus 19.8% (P = 0.021) for OHSS of any grade and 7.1% versus 14.1% (P = 0.027) for moderate/severe OHSS. The live birth rate per started cycle was 23.5% for individualized dosing and 18.6% for conventional dosing. CONCLUSIONS: Dosing with individualized follitropin delta in Japanese women is non-inferior to conventional dosing with follitropin beta for number of oocytes retrieved. The individualized approach shows a favourable benefit-risk profile, providing a statistically significant and clinically relevant reduction in the incidence of OHSS, without compromising live birth rates.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Ishihara O, Arce JC. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021. PMID: 33722477. doi:10.1016/j.rbmo.2021.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。